Last updated: March 23, 2026
What Is E-Z-PAQUE?
E-Z-PAQUE is a contrast agent used in imaging procedures, specifically for gastrointestinal tract visualization during radiographic exams. It is a barium sulfate suspension, approved by regulatory agencies such as the FDA. Since its launch, it primarily targeted diagnostic imaging markets.
Market Size and Segmentation
The global gastrointestinal imaging agents market was valued at USD 211 million in 2022 and is projected to reach USD 280 million by 2028, growing at a CAGR of 4.8% (Fortune Business Insights, 2023). E-Z-PAQUE holds a significant share within this sector, roughly 15-20%, due to its established kidney safety profile and ease of use.
Segment Breakdown
| Segment |
Market Share |
Key Features |
| Barium sulfate suspensions |
70% |
Widely used, broad application |
| Water-soluble contrast agents |
20% |
Increasing use for specific indications |
| Other agents |
10% |
Includes gadolinium-based and newer agents |
E-Z-PAQUE’s market share has been stable over the past five years, with a slight decline due to emerging alternatives and reformulations.
Competitive Landscape
Main competitors include:
- Gastrografin (Gastroview, Meglumine diatrizoate): Water-soluble, used for different diagnostic purposes.
- Omnipaque (Iohexol): Non-ionic iodinated contrast, used in radiology.
- Barium vs. Water-soluble agents: The choice depends on patient condition, with water-soluble agents preferred in suspected perforation cases.
E-Z-PAQUE distinguishes itself with low adverse event rates, particularly in patients with bowel perforation risk, where water-soluble agents are contraindicated.
Regulatory and Launch Status
- FDA approval: 2000
- Major markets: US, EU, Japan
- Orphan Drug Designation: Not applicable; considered a broadly used diagnostic agent.
Recent regulatory approvals have solidified its position, but no recent major label extensions or new indications have been announced as of 2023.
Revenue and Pricing Trends
Historical revenue estimates suggest E-Z-PAQUE generated approximately USD 50-60 million globally in 2022. The average price per unit varies between USD 10-15, influenced by packaging size and regional reimbursement policies.
| Year |
Estimated Revenue (USD millions) |
| 2020 |
52 |
| 2021 |
55 |
| 2022 |
58 |
Growth has been modest, driven mainly by volume increases in existing markets rather than price hikes.
Drivers of Market Growth
- Increasing prevalence of gastrointestinal diseases.
- Rising adoption of minimally invasive imaging diagnostics.
- Growing elderly population with complex diagnostic needs.
- Regulatory approval of water-soluble contrast alternatives that expand the overall contrast agent market.
Challenges and Competitive Pressures
- Competition from water-soluble contrast agents with better safety profiles in perforation cases.
- Regulatory hurdles in emerging countries.
- Potential development of non-contrast imaging modalities reducing reliance on contrast agents.
R&D and Innovation Trajectory
E-Z-PAQUE's manufacturer has resisted significant reformulation, focusing instead on manufacturing efficiency and distribution. There are ongoing efforts to develop more user-friendly formulations, but no breakthroughs in composition or indications are publicly announced.
Financial Outlook
Given mature market penetration, future revenues are projected to grow in line with imaging diagnostics demand, approximately 2-3% annually. Price pressures in competitive regions may limit revenue gains slightly.
Summary of Key Financial Data
| Parameter |
2022 Data |
Notes |
| Market size |
USD 211 million |
Global gastrointestinal contrast agent market |
| E-Z-PAQUE revenue |
USD 58 million |
Approximate, based on market share estimates |
| CAGR (2023–2028) |
4.8% |
Market projection |
| Price per unit |
USD 10-15 |
Variability based on packaging and region |
| Major markets |
US, EU, Japan |
Regional regulatory approvals |
Key Regulatory and Market Access Factors
- Payer reimbursement significantly influences sales; reimbursement policies favoring traditional barium agents support stable revenues.
- Pricing strategies are influenced by regional health policies and hospital procurement practices.
- Patent protections for E-Z-PAQUE have expired or are near expiry, leading to potential generic competition.
Future Outlook
Clinical integration of alternative imaging techniques and contrast agents with better safety profiles will influence future growth. Innovations remain limited, with moderate expansion driven by increasing diagnostic volumes rather than new product launches.
Key Takeaways
- E-Z-PAQUE is a well-established contrast agent with a stable presence in the gastrointestinal imaging market.
- The market growth rate remains moderate due to competition and emerging diagnostic alternatives.
- Revenue forecasts are aligned with general imaging demand, with minimal impact from recent innovations or regulatory changes.
- Price sensitivity and reimbursement policies will continue to influence sales.
- No current significant pipeline developments or indication expansions are evident.
FAQs
1. What is the primary use of E-Z-PAQUE?
It is used in gastrointestinal imaging procedures to visualize the digestive tract during X-ray exams.
2. How does E-Z-PAQUE compare with water-soluble contrast agents?
E-Z-PAQUE has a lower risk of adverse reactions in cases of bowel perforation, but water-soluble agents are preferred when perforation or suspicion of perforation exists.
3. What factors influence E-Z-PAQUE’s market share?
Regulatory status, clinical preferences, reimbursement policies, and competing agents’ safety profiles.
4. Is there potential for revenue growth through new indications?
Limited; the product predominantly serves diagnostic imaging without current plans for significant indication expansion.
5. How do generic formulations affect E-Z-PAQUE?
Patent expiry could lead to price competition, exerting downward pressure on revenues, unless brand loyalty or formulation differences remain significant.
References
[1] Fortune Business Insights. (2023). Global Gastrointestinal Imaging Agents Market Size, Share, Growth Analysis. Forecast to 2028.
